Statin effects on LDL and HDL cholesterol in South Asian and white populations

Journal of Clinical Pharmacology

Volumn 49, Issue 7, 2009, Pages 831-837

  Gupta, Milan ^a,b,c   Braga, Manoela F B ^a,b   Teoh, Hwee ^b,c   Tsigoulis, Michelle ^a,c   Verma, Subodh ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Canadian Cardiovascular Research Network   (Canada)

Author keywords

Coronary heart disease; LDL cholesterol; South Asian; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ASIAN; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

ANTICHOLESTEREMIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPTANOIC ACIDS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; TRIGLYCERIDES;

EID: 67650499583     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009334376     Document Type: Article

References (26)

1. Canada's Ethnocultural Mosaic, 2006 Census: National Picture. Ottawa, Ontario: Statistics Canada ; 2008.
2. American Community Survey: S0201: Selected Population Profile in the United States (Asian Indian). Washington, DC: US Census Bureau ; 2005.
3. Anand SS, Yusuf S. Risk factors for cardiovascular disease in Canadians of South Asian and European origin: a pilot study of the Study of Heart Assessment and Risk in Ethnic Groups (SHARE). Clin Invest Med. 1997 ; 20: 204-210. (Pubitemid 27376131)
4. Anand SS, Yusuf S., Vuksan V., et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000 ; 356: 279-284. (Pubitemid 30459585)
5. Gupta M., Doobay AV, Singh N., et al. Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects. CMAJ. 2002 ; 166: 717-722. (Pubitemid 34253120)
6. Gupta M., Singh N., Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation. 2006 ; 113: e924 - e929.
7. Sheth T., Nair C., Nargundkar M., Anand S., Yusuf S. Cardiovascular and cancer mortality among Canadians of European, South Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ. 1999 ; 161: 132-138. (Pubitemid 29375967)
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344: 1383-1389.
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996 ; 335: 1001-1009.
11. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003 ; 43: 943-967. (Pubitemid 37022739)
12. Liao JK Safety and efficacy of statins in Asians. Am J Cardiol. 2007 ; 99: 410-414. (Pubitemid 46149563)
13. Matsuzawa Y., Kita T., Mabuchi H., et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J. 2003 ; 67: 287-294.
14. Yamamoto A., Arakawa K., Sasaki J., et al. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study. J Atheroscler Thromb. 2002 ; 9: 48-56.
15. Wu CC, Sy R., Tanphaichitr V., Hin AT, Suyono S., Lee YT Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol: a multinational, multicenter, double-blind study. J Formos Med Assoc. 2002 ; 101: 478-487.
16. Kobayashi T., Homma Y. Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. J Clin Pharmacol. 2001 ; 41: 1055-1058. (Pubitemid 32880132)
17. McPherson R., Frohlich J., Fodor G., Genest J., Canadian Cardiovascular S. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006 ; 22: 913-927. (Pubitemid 44596492)
18. FDA Public Health Advisory on Crestor (rosuvastatin). http://www.fda.gov/CDER/Drug/advisory/crestor-3-2005.htm.
19. Gupta M., de Teresa E., Farsang C., et al. LDL-C and CRP lowering with atorvastatin in South Asians and Caucasians: insights from the ACTFAST study. Atherosclerosis. 2007 ; 8: 195.
20. Martineau P., Gaw A., de Teresa E., et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis. 2007 ; 191: 135-146. (Pubitemid 46227412)
21. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92: 152-160. (Pubitemid 36835963)
22. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696. (Pubitemid 39140624)
23. Deedwania PC, Gupta M., Stein M., Ycas J., Gold A. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol. 2007 ; 99: 1538-1543. (Pubitemid 46770637)
24. Poulter NR, Caulfield M., Feder G. Ethnic variations in response to a statin (EVIREST). J Hum Hypertens. 2001 ; 15 (suppl 1). S87 - S89.
25. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 ; 78: 330-341. (Pubitemid 41393668)
26. Tan CE, Loh LM, Tai ES Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience. Singapore Med J. 2003 ; 44: 635-638. (Pubitemid 38387322)